Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets.

PubWeight™: 2.99‹?› | Rank: Top 1%

🔗 View Article (PMC 1783835)

Published in Am J Gastroenterol on July 01, 2000

Authors

B J Reid1, D S Levine, G Longton, P L Blount, P S Rabinovitch

Author Affiliations

1: Fred Hutchinson Cancer Research Center, and Department of Medicine, University of Washington, Seattle 98104, USA.

Associated clinical trials:

Progression of Gastroesophageal Reflux Disease and Barrett's Esophagus and the Creation of a Barrett's Registry | NCT00574327

The Study of Barrett's Esophagus: What Are the Factors of Progression (BEST) | NCT00586404

Articles citing this

(truncated to the top 100)

Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis. Nat Rev Cancer (2010) 3.27

Long-term survival following endoscopic and surgical treatment of high-grade dysplasia in Barrett's esophagus. Gastroenterology (2007) 2.86

American Gastroenterological Association technical review on the management of Barrett's esophagus. Gastroenterology (2011) 2.50

Targeted imaging of esophageal neoplasia with a fluorescently labeled peptide: first-in-human results. Sci Transl Med (2013) 2.30

NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma. PLoS Med (2007) 2.23

Predictors of progression in Barrett's esophagus III: baseline flow cytometric variables. Am J Gastroenterol (2001) 2.21

Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am J Gastroenterol (2001) 2.17

A cost-utility analysis of ablative therapy for Barrett's esophagus. Gastroenterology (2009) 1.95

Utility of biomarkers in prediction of response to ablative therapy in Barrett's esophagus. Gastroenterology (2008) 1.87

Molecular imaging using fluorescent lectins permits rapid endoscopic identification of dysplasia in Barrett's esophagus. Nat Med (2012) 1.83

Elastic scattering spectroscopy accurately detects high grade dysplasia and cancer in Barrett's oesophagus. Gut (2006) 1.78

Quality of life following radiofrequency ablation of dysplastic Barrett's esophagus. Endoscopy (2010) 1.75

The cost effectiveness of radiofrequency ablation for Barrett's esophagus. Gastroenterology (2012) 1.65

Reproducible two-dimensional capillary electrophoresis analysis of Barrett's esophagus tissues. Anal Chem (2006) 1.49

Surveillance for low-grade dysplastic Barrett's oesophagus: one size fits all? World J Surg (2015) 1.45

Single nucleotide polymorphism-based genome-wide chromosome copy change, loss of heterozygosity, and aneuploidy in Barrett's esophagus neoplastic progression. Cancer Prev Res (Phila) (2008) 1.43

Prediction of response to endoscopic therapy of Barrett's dysplasia by using genetic biomarkers. Gastrointest Endosc (2014) 1.41

Extended lifespan of Barrett's esophagus epithelium transduced with the human telomerase catalytic subunit: a useful in vitro model. Carcinogenesis (2003) 1.39

Global DNA methylation patterns in Barrett's esophagus, dysplastic Barrett's, and esophageal adenocarcinoma are associated with BMI, gender, and tobacco use. Clin Epigenetics (2016) 1.39

Predictors of progression in Barrett's esophagus: current knowledge and future directions. Am J Gastroenterol (2010) 1.35

Temporal and spatial evolution of somatic chromosomal alterations: a case-cohort study of Barrett's esophagus. Cancer Prev Res (Phila) (2013) 1.31

What is the best management strategy for high grade dysplasia in Barrett's oesophagus? A cost effectiveness analysis. Gut (2004) 1.29

Association between markers of obesity and progression from Barrett's esophagus to esophageal adenocarcinoma. Clin Gastroenterol Hepatol (2013) 1.29

Barrett's oesophagus: from metaplasia to dysplasia and cancer. Gut (2005) 1.18

Chromosomal instability and copy number alterations in Barrett's esophagus and esophageal adenocarcinoma. Clin Cancer Res (2009) 1.17

Detection of endogenous biomolecules in Barrett's esophagus by Fourier transform infrared spectroscopy. Proc Natl Acad Sci U S A (2007) 1.16

A comparison of conventional cytology, DNA ploidy analysis, and fluorescence in situ hybridization for the detection of dysplasia and adenocarcinoma in patients with Barrett's esophagus. Hum Pathol (2008) 1.12

Barrett's esophagus and the increasing role of endoluminal therapy. Therap Adv Gastroenterol (2008) 1.11

Endoscopic mucosal resection for high-grade dysplasia and intramucosal carcinoma in Barrett's esophagus: an Italian experience. World J Gastroenterol (2005) 1.10

DNA promoter hypermethylation of p16 and APC predicts neoplastic progression in Barrett's esophagus. Am J Gastroenterol (2009) 1.08

The role of tobacco, alcohol, and obesity in neoplastic progression to esophageal adenocarcinoma: a prospective study of Barrett's esophagus. PLoS One (2013) 1.08

Urinary metabolomic signature of esophageal cancer and Barrett's esophagus. World J Surg Oncol (2012) 1.04

Epigenetic biomarkers in esophageal cancer. Cancer Lett (2012) 1.01

Barrett's esophagus: Incidence, etiology, pathophysiology, prevention and treatment. Ther Clin Risk Manag (2007) 1.00

Serum selenium levels in relation to markers of neoplastic progression among persons with Barrett's esophagus. J Natl Cancer Inst (2003) 0.99

Biomarkers in Barrett's esophagus and esophageal adenocarcinoma: predictors of progression and prognosis. World J Gastroenterol (2010) 0.98

Cell proliferation, cell cycle abnormalities, and cancer outcome in patients with Barrett's esophagus: a long-term prospective study. Clin Cancer Res (2008) 0.98

Are screening and surveillance for Barrett's oesophagus really worthwhile? Gut (2005) 0.97

Barrett's oesophagus: the continuing conundrum. BMJ (2000) 0.97

Predictive factors of coexisting cancer in Barrett's high-grade dysplasia. Surg Endosc (2006) 0.96

Barrett esophagus: histology and pathology for the clinician. Nat Rev Gastroenterol Hepatol (2009) 0.95

HER-2 overexpression/amplification in Barrett's oesophagus predicts early transition from dysplasia to adenocarcinoma: a clinico-pathologic study. J Cell Mol Med (2008) 0.95

Selenium, selenoenzymes, oxidative stress and risk of neoplastic progression from Barrett's esophagus: results from biomarkers and genetic variants. PLoS One (2012) 0.94

Chromosome 4 hyperploidy represents an early genetic aberration in premalignant Barrett's oesophagus. Gut (2003) 0.93

DNA methylation profiling in Barrett's esophagus and esophageal adenocarcinoma reveals unique methylation signatures and molecular subclasses. Epigenetics (2011) 0.93

Diagnosis and grading of dysplasia in Barrett's oesophagus. J Clin Pathol (2006) 0.93

Approach to early Barrett's cancer. World J Surg (2003) 0.93

Endoscopic ablation of intestinal metaplasia containing high-grade dysplasia in esophagectomy patients using a balloon-based ablation system. Surg Endosc (2006) 0.92

DNA index determination with Automated Cellular Imaging System (ACIS) in Barrett's esophagus: comparison with CAS 200. BMC Clin Pathol (2005) 0.92

Image cytometry accurately detects DNA ploidy abnormalities and predicts late relapse to high-grade dysplasia and adenocarcinoma in Barrett's oesophagus following photodynamic therapy. Br J Cancer (2010) 0.91

Mitigating fluorescence spectral overlap in wide-field endoscopic imaging. J Biomed Opt (2013) 0.90

Biomarkers for dysplastic Barrett's: ready for prime time? World J Surg (2015) 0.89

Comparison of six immunohistochemical markers for the histologic diagnosis of neoplasia in Barrett's esophagus. Virchows Arch (2010) 0.89

Can extent of high grade dysplasia in Barrett's oesophagus predict the presence of adenocarcinoma at oesophagectomy? Gut (2003) 0.89

Photodynamic therapy vs radiofrequency ablation for Barrett's dysplasia: efficacy, safety and cost-comparison. World J Gastroenterol (2013) 0.89

Cornelia de Lange syndrome - characteristics and laparoscopic treatment modalities of reflux based on own material. Wideochir Inne Tech Maloinwazyjne (2011) 0.89

Dietary supplement use and risk of neoplastic progression in esophageal adenocarcinoma: a prospective study. Nutr Cancer (2008) 0.89

Genetic variation in GPX1 is associated with GPX1 activity in a comprehensive analysis of genetic variations in selenoenzyme genes and their activity and oxidative stress in humans. J Nutr (2012) 0.89

Barrett's Esophagus: A Comprehensive and Contemporary Review for Pathologists. Am J Surg Pathol (2016) 0.88

Endoscopic mucosal resection of large hyperplastic polyps in 3 patients with Barrett's esophagus. World J Gastroenterol (2006) 0.88

Comparison of nuclear texture analysis and image cytometric DNA analysis for the assessment of dysplasia in Barrett's oesophagus. Br J Cancer (2011) 0.88

Translation of an STR-based biomarker into a clinically compatible SNP-based platform for loss of heterozygosity. Cancer Biomark (2009) 0.87

Biomarkers and molecular diagnosis of gastrointestinal and pancreatic neoplasms. Nat Rev Gastroenterol Hepatol (2010) 0.87

Assessment of Esophageal Adenocarcinoma Risk Using Somatic Chromosome Alterations in Longitudinal Samples in Barrett's Esophagus. Cancer Prev Res (Phila) (2015) 0.87

Revisiting tumour aneuploidy - the place of ploidy assessment in the molecular era. Nat Rev Clin Oncol (2015) 0.87

Color-matched and fluorescence-labeled esophagus phantom and its applications. J Biomed Opt (2013) 0.87

Endoscopic mucosal resection of Barrett's oesophagus containing dysplasia or intramucosal cancer. Postgrad Med J (2007) 0.86

Correlation of histology with biomarker status after photodynamic therapy in Barrett esophagus. Cancer (2008) 0.86

Zoning of mucosal phenotype, dysplasia, and telomerase activity measured by telomerase repeat assay protocol in Barrett's esophagus. Neoplasia (2004) 0.85

Pathophysiology and treatment of Barrett's esophagus. World J Gastroenterol (2010) 0.85

Lugol chromoendoscopy combined with brush cytology in patients at risk for esophageal squamous cell carcinoma. Surg Endosc (2009) 0.85

Barrett's oesophagus: an ideal model to study cancer genetics. Hum Genet (2009) 0.84

Optimal conditions for successful ablation of high-grade dysplasia in Barrett's oesophagus using aminolaevulinic acid photodynamic therapy. Lasers Med Sci (2008) 0.84

Management of Barrett's esophageal carcinoma. Surg Today (2013) 0.84

How light dosimetry influences the efficacy of photodynamic therapy with 5-aminolaevulinic acid for ablation of high-grade dysplasia in Barrett's esophagus. Lasers Med Sci (2007) 0.83

Early events during neoplastic progression in Barrett's esophagus. Cancer Biomark (2010) 0.83

Barrett's esophagus: A review of diagnostic criteria, clinical surveillance practices and new developments. J Gastrointest Oncol (2012) 0.83

Barrett's esophagus and cancer risk: how research advances can impact clinical practice. Gut Liver (2014) 0.82

Inflammation and oxidative stress markers and esophageal adenocarcinoma incidence in a Barrett's esophagus cohort. Cancer Epidemiol Biomarkers Prev (2014) 0.82

Barrett's esophagus with high-grade dysplasia: focus on current treatment options. World J Gastroenterol (2011) 0.82

Molecular markers and staging of early esophageal cancer. Langenbecks Arch Surg (2003) 0.82

The Role of Gastroesophageal Reflux and Other Factors during Progression to Esophageal Adenocarcinoma. Cancer Epidemiol Biomarkers Prev (2015) 0.82

Nonadenomatous dysplasia in barrett esophagus: a clinical, pathologic, and DNA content flow cytometric study. Am J Surg Pathol (2009) 0.82

Magnitude of Missed Esophageal Adenocarcinoma After Barrett's Esophagus Diagnosis: A Systematic Review and Meta-analysis. Gastroenterology (2015) 0.81

High Goblet Cell Count Is Inversely Associated with Ploidy Abnormalities and Risk of Adenocarcinoma in Barrett's Esophagus. PLoS One (2015) 0.81

Correlation of the presence and extent of loss of heterozygosity mutations with histological classifications of Barrett's esophagus. BMC Gastroenterol (2012) 0.81

Genetic Insights in Barrett's Esophagus and Esophageal Adenocarcinoma. Gastroenterology (2015) 0.81

Barrett's Esophagus: Diagnosis, Screening, Surveillance, and Controversies. Gut Liver (2007) 0.80

Assessment of mutational load in biopsy tissue provides additional information about genomic instability to histological classifications of Barrett's esophagus. J Gastrointest Cancer (2014) 0.79

Ablative mucosectomy is the procedure of choice to prevent Barrett's cancer. Gut (2003) 0.79

Aberrantly methylated PKP1 in the progression of Barrett's esophagus to esophageal adenocarcinoma. Genes Chromosomes Cancer (2011) 0.79

"Indefinite for Dysplasia" in Barrett's Esophagus: Inflammation and DNA Content Abnormality are Significant Predictors of Early Detection of Neoplasia. Clin Transl Gastroenterol (2015) 0.79

Genetic Biomarkers of Barrett's Esophagus Susceptibility and Progression to Dysplasia and Cancer: A Systematic Review and Meta-Analysis. Dig Dis Sci (2015) 0.79

Epidemiology of Barrett's Esophagus and Esophageal Adenocarcinoma. Gastroenterol Clin North Am (2015) 0.79

Minimally invasive esophagectomy for Barrett's with high-grade dysplasia and early adenocarcinoma of the esophagus. J Gastrointest Surg (2010) 0.79

Screening, surveillance, and prevention for esophageal cancer. Gastroenterol Clin North Am (2009) 0.79

Barrett's Esophagus: Emerging Knowledge and Management Strategies. Patholog Res Int (2012) 0.78

Beyond Field Effect: Analysis of Shrunken Centroids in Normal Esophageal Epithelia Detects Concomitant Esophageal Adenocarcinoma. Bioinform Biol Insights (2007) 0.78

Molecular changes in the progression of Barrett's oesophagus. Postgrad Med J (2007) 0.78

Diagnosis and management of Barrett's esophagus. Surg Clin North Am (2012) 0.78

Articles cited by this

Impact of hospital volume on operative mortality for major cancer surgery. JAMA (1998) 11.05

Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer (1998) 10.17

Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology (1997) 8.51

An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's esophagus. Gastroenterology (1993) 5.41

Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol (1998) 4.68

The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. Am J Gastroenterol (1997) 4.52

The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus. N Engl J Med (1985) 4.30

Barrett's esophagus: development of dysplasia and adenocarcinoma. Gastroenterology (1989) 4.23

Observer variation in the diagnosis of dysplasia in Barrett's esophagus. Hum Pathol (1988) 3.67

Barrett's esophagus. A prevalent, occult complication of gastroesophageal reflux disease. Gastroenterology (1987) 3.56

Adenocarcinoma and Barrett's esophagus. An overrated risk? Gastroenterology (1984) 3.36

Barrett's esophagus, dysplasia, and adenocarcinoma. Hum Pathol (1994) 2.97

A hospital's annual rate of esophagectomy influences the operative mortality rate. J Gastrointest Surg (1999) 2.87

Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus. Gut (1996) 2.75

Photodynamic therapy for Barrett's esophagus: follow-up in 100 patients. Gastrointest Endosc (1999) 2.65

Flow-cytometric and histological progression to malignancy in Barrett's esophagus: prospective endoscopic surveillance of a cohort. Gastroenterology (1992) 2.57

17p (p53) allelic losses, 4N (G2/tetraploid) populations, and progression to aneuploidy in Barrett's esophagus. Proc Natl Acad Sci U S A (1996) 2.53

Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk. Am J Gastroenterol (1999) 2.50

Prevalence of metaplasia at the gastro-oesophageal junction. Lancet (1994) 2.45

Only patients with dysplasia progress to adenocarcinoma in Barrett's oesophagus. Gut (1991) 2.29

The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: report on the Cleveland Clinic Barrett's Esophagus Registry. Am J Gastroenterol (1999) 2.26

Outcome of adenocarcinoma arising in Barrett's esophagus in endoscopically surveyed and nonsurveyed patients. J Thorac Cardiovasc Surg (1994) 2.25

Barrett's esophagus. Correlation between flow cytometry and histology in detection of patients at risk for adenocarcinoma. Gastroenterology (1987) 2.15

The rising trend in oesophageal adenocarcinoma and gastric cardia. Eur J Cancer Prev (1992) 2.05

Barrett's esophagus. Prevalence and incidence of adenocarcinoma. Arch Intern Med (1991) 2.01

Value of endoscopic surveillance in the detection of neoplastic change in Barrett's oesophagus. Br J Surg (1988) 1.91

Dysplasia and deoxyribonucleic acid aneuploidy in the assessment of precancerous changes in chronic ulcerative colitis. Observer variation and correlations. Gastroenterology (1988) 1.81

Guidelines for implementation of clinical DNA cytometry. International Society for Analytical Cytology. Cytometry (1993) 1.77

Discordance between flow cytometric abnormalities and dysplasia in Barrett's esophagus. Gastroenterology (1989) 1.61

Barrett's esophagus: does the incidence of adenocarcinoma matter? Am J Gastroenterol (1997) 1.58

Interlaboratory reproducibility of semiautomated cell cycle analysis of flow cytometry DNA-histograms obtained from fresh material of 1,295 breast cancer cases. Hum Pathol (1996) 1.58

Flow cytometry in Barrett's esophagus. What have we learned so far? Dig Dis Sci (1991) 1.48

Variable pathologic interpretation of columnar lined esophagus by general pathologists in community practice. Gastrointest Endosc (1999) 1.45

Determinants of survival following the diagnosis of esophageal adenocarcinoma (United States). Cancer Causes Control (1996) 1.35

DNA content histogram and cell-cycle analysis. Methods Cell Biol (1994) 1.32

Practice patterns for surveillance of Barrett's esophagus in the united states. Gastrointest Endosc (2000) 1.29

The cost of surveillance for adenocarcinoma complicating Barrett's esophagus. Am J Gastroenterol (1988) 1.24

Reversal of Barrett's esophagus with acid suppression and multipolar electrocoagulation: preliminary results. Gastrointest Endosc (1996) 1.16

DNA/protein flow cytometry as a predictive marker of malignancy in dysplasia-free Barrett's esophagus: thirteen-year follow-up study on a cohort of patients. Cytometry (1998) 1.13

Clinical decision making in Barrett's oesophagus can be supported by computerized immunoquantitation and morphometry of features associated with proliferation and differentiation. J Pathol (1998) 1.09

Adenocarcinoma arising in Barrett's esophagus. Dig Dis Sci (1989) 1.06

[Reproducibility of histological criteria of dysplasia in Barrett mucosa]. Gastroenterol Clin Biol (1994) 1.00

Biomarkers in Barrett's esophagus (review). Int J Oncol (1998) 0.88

Surveillance for Barrett's esophagus: are we saving lives? Gastroenterology (1997) 0.87

[Flow cytometric analysis of cellular DNA content in Barret's esophagus. A study of 66 cases]. Gastroenterol Clin Biol (1991) 0.86

Autolysis is a potential source of false aneuploid peaks in flow cytometric DNA histograms. Cytometry (1989) 0.85

Interlaboratory variation in DNA flow cytometry. Results of the College of American Pathologists' Survey. Arch Pathol Lab Med (1994) 0.81

Proceedings from an international conference on ablation therapy for Barrett's mucosa. Brittany, France, 31 August-2 September 1997. Dis Esophagus (1998) 0.81

Flow cytometry and Barrett's esophagus. Dig Dis Sci (1992) 0.81

Quality control study of the Italian Group of Cytometry on flow cytometry DNA content measurements: II. Factors affecting inter- and intralaboratory variability. Cytometry (1997) 0.80

Articles by these authors

An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's esophagus. Gastroenterology (1993) 5.41

On estimating HLA/disease association with application to a study of aplastic anemia. Biometrics (1991) 4.81

Evolution of neoplastic cell lineages in Barrett oesophagus. Nat Genet (1999) 3.30

Heterogeneity among T cells in intracellular free calcium responses after mitogen stimulation with PHA or anti-CD3. Simultaneous use of indo-1 and immunofluorescence with flow cytometry. J Immunol (1986) 3.08

Physicians' perceptions of dysplasia and approaches to surveillance colonoscopy in ulcerative colitis. Am J Gastroenterol (1995) 2.73

Optimizing endoscopic biopsy detection of early cancers in Barrett's high-grade dysplasia. Am J Gastroenterol (2000) 2.58

Flow-cytometric and histological progression to malignancy in Barrett's esophagus: prospective endoscopic surveillance of a cohort. Gastroenterology (1992) 2.57

Mutations in the p53 gene: an early marker of neoplastic progression in ulcerative colitis. Gastroenterology (1994) 2.55

17p (p53) allelic losses, 4N (G2/tetraploid) populations, and progression to aneuploidy in Barrett's esophagus. Proc Natl Acad Sci U S A (1996) 2.53

Crosslinking of surface antigens causes mobilization of intracellular ionized calcium in T lymphocytes. Proc Natl Acad Sci U S A (1987) 2.53

DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis. Gastroenterology (1992) 2.48

Neoplastic progression in ulcerative colitis: histology, DNA content, and loss of a p53 allele. Gastroenterology (1992) 2.35

Predictors of progression in Barrett's esophagus III: baseline flow cytometric variables. Am J Gastroenterol (2001) 2.21

CD28 ligation in T-cell activation: evidence for two signal transduction pathways. Blood (1990) 2.21

Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am J Gastroenterol (2001) 2.17

Barrett's esophagus. Correlation between flow cytometry and histology in detection of patients at risk for adenocarcinoma. Gastroenterology (1987) 2.15

Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood (1992) 2.14

Targeted gene walking polymerase chain reaction. Nucleic Acids Res (1991) 2.14

Identification and functional characterization of two distinct epitopes on the human T cell surface protein Tp50. J Immunol (1983) 2.13

p16(INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium. Cancer Res (2001) 2.06

Effect of segment length on risk for neoplastic progression in patients with Barrett esophagus. Ann Intern Med (2000) 2.05

Evaluation of p53 protein expression in Barrett's esophagus by two-parameter flow cytometry. Gastroenterology (1992) 2.03

Barrett's esophagus: cell cycle abnormalities in advancing stages of neoplastic progression. Gastroenterology (1993) 2.00

Antibody binding to CD5 (Tp67) and Tp44 T cell surface molecules: effects on cyclic nucleotides, cytoplasmic free calcium, and cAMP-mediated suppression. J Immunol (1986) 1.89

An apoptosis-inducing genotoxin differentiates heterozygotic carriers for Werner helicase mutations from wild-type and homozygous mutants. Hum Genet (1997) 1.88

Risk and natural history of colonic neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis. Gastroenterology (1996) 1.82

Guidelines for implementation of clinical DNA cytometry. International Society for Analytical Cytology. Cytometry (1993) 1.77

CD19 monoclonal antibody HD37 inhibits anti-immunoglobulin-induced B cell activation and proliferation. J Immunol (1987) 1.76

Microsatellite instability in nonneoplastic mucosa from patients with chronic ulcerative colitis. Cancer Res (1996) 1.74

Werner syndrome lymphoblastoid cells are sensitive to camptothecin-induced apoptosis in S-phase. Hum Genet (1999) 1.71

Signal transduction through CD4 receptors: stimulatory vs. inhibitory activity is regulated by CD4 proximity to the CD3/T cell receptor. Eur J Immunol (1988) 1.68

Loss of heterozygosity involves multiple tumor suppressor genes in human esophageal cancers. Cancer Res (1992) 1.65

Oral beclomethasone dipropionate for treatment of intestinal graft-versus-host disease: a randomized, controlled trial. Gastroenterology (1998) 1.65

Analysis of c-Ki-ras mutations in human colon carcinoma by cell sorting, polymerase chain reaction, and DNA sequencing. Cancer Res (1989) 1.63

c-Ki-ras mutations in chronic ulcerative colitis and sporadic colon carcinoma. Gastroenterology (1990) 1.59

Histological and anatomic changes in Barrett's esophagus after antireflux surgery. Am J Gastroenterol (1999) 1.59

Loss of heterozygosity involving the APC and MCC genetic loci occurs in the majority of human esophageal cancers. Proc Natl Acad Sci U S A (1992) 1.56

A neural network theory of proportional analogy-making. Neural Netw (2000) 1.53

Distinct patterns of transmembrane calcium flux and intracellular calcium mobilization after differentiation antigen cluster 2 (E rosette receptor) or 3 (T3) stimulation of human lymphocytes. J Clin Invest (1986) 1.53

Differential proliferation of fibroblasts cultured from normal and fibrotic human lungs. Am Rev Respir Dis (1988) 1.53

Formation of the tetraploid intermediate is associated with the development of cells with more than four centrioles in the elastase-simian virus 40 tumor antigen transgenic mouse model of pancreatic cancer. Proc Natl Acad Sci U S A (1991) 1.53

17p allelic losses in diploid cells of patients with Barrett's esophagus who develop aneuploidy. Cancer Res (1994) 1.52

Smooth muscle cell hypertrophy versus hyperplasia in hypertension. Proc Natl Acad Sci U S A (1981) 1.51

Werner syndrome cells are sensitive to DNA cross-linking drugs. FASEB J (2001) 1.48

Marrow transplantation for Fanconi anaemia: conditioning with reduced doses of cyclophosphamide without radiation. Br J Haematol (1996) 1.47

p53 mutations in Barrett's adenocarcinoma and high-grade dysplasia. Gastroenterology (1994) 1.43

Induction of calcium flux and enhancement of cytolytic activity in natural killer cells by cross-linking of the sheep erythrocyte binding protein (CD2) and the Fc-receptor (CD16). J Immunol (1987) 1.42

17p allelic deletions and p53 protein overexpression in Barrett's adenocarcinoma. Cancer Res (1991) 1.39

Barrett's esophagus: ordering the events that lead to cancer. Eur J Cancer Prev (1996) 1.39

Incorporating the time dimension in receiver operating characteristic curves: a case study of prostate cancer. Med Decis Making (1999) 1.38

Stimulation of T cells through the CD3/T-cell receptor complex: role of cytoplasmic calcium, protein kinase C translocation, and phosphorylation of pp60c-src in the activation pathway. Mol Cell Biol (1987) 1.32

The role of cyclooxygenase 2 in ulcerative colitis-associated neoplasia. Am J Pathol (2000) 1.27

Transplantation of hematopoietic stem cells obtained by a combined dye method fractionation of murine bone marrow. Blood (1990) 1.26

Safety of a systematic endoscopic biopsy protocol in patients with Barrett's esophagus. Am J Gastroenterol (2000) 1.25

CD5 antibodies increase intracellular ionized calcium concentration in T cells. J Immunol (1987) 1.24

Genetic analysis of long-term Barrett's esophagus epithelial cultures exhibiting cytogenetic and ploidy abnormalities. Gastroenterology (1998) 1.24

Role of the CD22 human B cell antigen in B cell triggering by anti-immunoglobulin. J Immunol (1988) 1.19

Effects of cytoskeletal disrupting agents on replication of bovine endothelium. J Cell Physiol (1981) 1.19

A marginal regression modelling framework for evaluating medical diagnostic tests. Stat Med (1997) 1.19

Antigen-independent regulation of cytoplasmic calcium in B cells with a 12-kDa B-cell growth factor and anti-CD19. Proc Natl Acad Sci U S A (1988) 1.18

Previous donor pregnancy as a risk factor for acute graft-versus-host disease in patients with aplastic anaemia treated by allogeneic marrow transplantation. Br J Haematol (1990) 1.17

De novo synthesis of glutathione is required for both entry into and progression through the cell cycle. J Cell Physiol (1995) 1.16

Comparative heterokaryon study of cellular senescence and the serum-deprived state. Exp Cell Res (1980) 1.16

Improved sensitivity in flow cytometric intracellular ionized calcium measurement using fluo-3/Fura Red fluorescence ratios. Cytometry (1994) 1.12

Simultaneous cell cycle analysis and two-color surface immunofluorescence using 7-amino-actinomycin D and single laser excitation: applications to study of cell activation and the cell cycle of murine Ly-1 B cells. J Immunol (1986) 1.12

Consensus review of the clinical utility of DNA flow cytometry in colorectal cancer. Cytometry (1993) 1.11

Regulation of human fibroblast growth rate by both noncycling cell fraction transition probability is shown by growth in 5-bromodeoxyuridine followed by Hoechst 33258 flow cytometry. Proc Natl Acad Sci U S A (1983) 1.11

Distribution of aneuploid cell populations in ulcerative colitis with dysplasia or cancer. Gastroenterology (1991) 1.11

Barrett's esophagus. Correlation between mucin histochemistry, flow cytometry, and histologic diagnosis for predicting increased cancer risk. Am J Pathol (1988) 1.10

Disruption of redox homeostasis in tumor necrosis factor-induced apoptosis in a murine hepatocyte cell line. Am J Pathol (2000) 1.09

High-quality RNA and DNA from flow cytometrically sorted human epithelial cells and tissues. Biotechniques (2002) 1.08

Deletion mapping of chromosome 8p in colorectal carcinoma and dysplasia arising in ulcerative colitis, prostatic carcinoma, and malignant fibrous histiocytomas. Am J Pathol (1994) 1.08

Cytokeratin labeling of breast cancer cells extracted from paraffin-embedded tissue for bivariate flow cytometric analysis. Cytometry (1996) 1.08

Frequency and spectrum of c-Ki-ras mutations in human sporadic colon carcinoma, carcinomas arising in ulcerative colitis, and pancreatic adenocarcinoma. Environ Health Perspect (1991) 1.07

The management of high grade dysplasia and early cancer in Barrett's esophagus. A multidisciplinary problem. Cancer (1994) 1.05

Neural dynamics of attentionally modulated Pavlovian conditioning: blocking, interstimulus interval, and secondary reinforcement. Appl Opt (1987) 1.04

Cultured renal epithelial cells from birds and mice: enhanced resistance of avian cells to oxidative stress and DNA damage. J Gerontol A Biol Sci Med Sci (1998) 1.03

Endogenous blockage and delay of the chromosome cycle despite normal recruitment and growth phase explain poor proliferation and frequent edomitosis in Fanconi anemia cells. Am J Hum Genet (1985) 1.01

Bone density loss after allogeneic hematopoietic stem cell transplantation: a prospective study. Biol Blood Marrow Transplant (2001) 1.01

Anti-HEL cell monoclonal antibodies recognize determinants that are also present in hemopoietic progenitors. Blood (1984) 1.00